Article

SS18-SSX co-opts P300 to sustain oncogenic transcription independent of SWI/SNF activity

2026-01-27

Abstract excerpt

<h4>SUMMARY</h4> Synovial sarcoma is driven by the SS18-SSX fusion oncoprotein, which has been assumed to promote tumorigenesis through its incorporation into the SWI/SNF chromatin remodeling complexes. Accordingly, therapeutic efforts have focused on targeting SS18-SSX containing SWI/SNF assemblies, yet these approaches have produced limited clinical benefit. Here, we demonstrate that SS18-SSX sustains oncogenic...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d380b523-623a-50ec-b534-7b94ce155a0a
DOI: 10.64898/2026.01.26.701706

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

SS18-SSX co-opts P300 to sustain oncogenic transcription independent of SWI/SNF activityDOI 10.64898/2026.01.26.701706Read

Aberrant gene activation in synovial sarcoma relies on SSX specificity and increased PRC1.1 stabilitySemantic proximity Read

An autoregulatory feedback loop converging on H2A ubiquitination drives synovial sarcomaSemantic proximity Read

Synovial Sarcoma Chromatin Dynamics Reveal a Continuum in SS18:SSX ReprogramingSemantic proximity Read

Targeting of SUMOylation leads to cBAF complex stabilization and disruption of the SS18::SSX transcriptome in Synovial SarcomaSemantic proximity Read

Targeting of SUMOylation leads to cBAF complex stabilization and disruption of the SS18::SSX transcriptome in Synovial SarcomaSemantic proximity Read

SS18::SSX redistributes BAF chromatin remodelers selectively to activate and repress transcriptionSemantic proximity Read

Molecular and epigenetic oncogenesis in synovial sarcoma: implications for cancer biology, diagnosis and treatmentSemantic proximity Read

Synovial Sarcoma: Recent Discoveries as a Roadmap to New Avenues for TherapySemantic proximity Read

Cell-of-origin epigenome underlies SS18::SSX-mediated transformationSemantic proximity Read

Pharmacologic degradation of WDR5 suppresses oncogenic activities of SS18::SSX and provides a therapeutic of synovial sarcomaSemantic proximity Read

Histone Deacetylase Inhibitors Reverse SS18-SSX–Mediated Polycomb Silencing of the Tumor Suppressor <i>Early Growth Response 1</i> in Synovial SarcomaSemantic proximity Read

SUMO2 Inhibition Reverses Aberrant Epigenetic Rewiring Driven by Synovial Sarcoma Fusion Oncoproteins and Impairs SarcomagenesisSemantic proximity Read